LOADING
With EU regulations, Declaration of Helsinki and ICH GCP standards.
Rapid initiation and conduct of clinical trials – less than 30 days.
Highly qualified physicians, experienced researchers, and clinical trial specialists.
Best “price-quality” ratio in Europe and Worldwide.
Phases I through IV, interventional & observational, every therapeutic area & indication.
U.S. ranks as the #1 country by number of Clinical Trials registered.
In the vaccine manufacturing sector, new methodological approaches are being developed to produce vaccines very quickly.
Health Canada has a fixed 30-day review for standard trials and a 7-day review for bioequivalence studies
Data from Canadian trials, conducted under ICH-GCP standards, is fully accepted by FDA and EMA
Features a diverse population and comprehensive, linkable health data (pharmacy, claims, EMR)
With 130 million people, Mexico offers a large patient pool for common and rare disease
Mexico’s location facilitates efficient logistics to the US and acts as a gateway to Latin American markets, supported by trade agreements like the USMCA
A new fast-track system features a 14-day maximum assessment for Phase I trials.
The UK actively integrates novel methods like in-silico (computer model) trials.
The NHS provides access to a large, engaged patient pool, with over 450,000 research participants last year in England.
Second in Europe for oncology trials; 45% of French trials are in oncology
Home to one of the world’s largest linked health databases (SNDS)
Ranked 2nd/3rd in Europe for trial participation; part of the coordinated F-CRIN network
Poland is a top European destination for oncology trials, with many large centers and high recruitment rates
A key national strength is the actively engaged Medical Research Agency and the coordinated Polish Clinical Trials Network (PCTN) of support centers
Italy is a top European destination for clinical trials with world-class oncology centers and demonstrated high patient enrollmen
Sponsors benefit from Italy’s single, predictable application fee, while the public healthcare system realizes significant savings by providing investigational therapies
Italy supports trials through ItaCRIN, a national network providing methodological, regulatory, and management support for multinational studies
Recruitment from specialized national centers accelerates enrollment.
Experienced investigators and rigorous standards contribute to a strong track record of successful regulatory inspections.
Investment in hubs like Bio City and supportive frameworks for advanced therapies provide a foundation for complex trials.
The overall process for standard trial applications is often completed within 60 days
Croatia is actively strengthening its health data ecosystem, including joining SNOMED International to improve data interoperability for research
Research institutes collaborate with large private outpatient providers, granting access to extensive networks of healthcare professionals for recruitment
A population of ~6.58 million, with ~22% over 65, offers access to a substantial, treatment-naïve patient pool for age-related and other prevalent conditions.
Recent rule changes now permit Phase I trials in private healthcare institutions, expanding site options and aligning with ICH standards.
An extensive network of university hospitals and clinics provides high-caliber sites and GCP-trained investigators
The country offers competitive operational costs while maintaining Western-comparable quality standards
The country offers a cost-efficient environment with operational expenses notably lower than in Western Europe and North America
The country has a strong reputation for producing high-quality clinical data that meets international standards for regulatory submission
We conduct clinical trials for medicinal products, medical devices and in-vitro diagnostics across the entire product lifecycle.
Our core strengths include Phase I–IV interventional trials, bioequivalence studies, and observational research in Ukraine, Canada, North America, Mexico, Poland, France, Italy, United Kingdom, Serbia, Romania, Lithuania, Croatia, Latvia and Georgia.
Classical randomized and controlled trials – our primary area of expertise.
Our expertise in this area includes:
Non-interventional evaluation of treatment practices and real-world patient outcomes.
Our expertise in this area includes:
We actively collaborate with generic and biosimilar manufacturers, supporting comparative studies with precision and speed.
Our expertise in this area includes:
